Please assess the completion status of the following clinical trial:

Trial Title: Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic confirmation of NSCLC.~* Patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.~* Unresectable phase IIIA(N2) and IIIB lung cancer confirmed by PET/CT, CT or MRI.~* Whole lung V20\>=35% when giving 60Gy which is the minimum dose of radical irradiation.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.~* Previously treated with chemotherapy or treatment-naive~* No previous chest radiotherapy, immunotherapy or biotherapy~* Hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL~* Serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60 ml/min~* Bilirubin ≤1.5 times UNL, AST（SGOT）≤2.5 times UNL ,ALT（SGPT）≤2.5 times UNL,alkaline phosphatase ≤5 times UNL~* FEV1 \>0.8 L~* CB6 within normal limits~* patients and their family signed the informed consents~Exclusion Criteria:~* Previous or recent another malignancy, except nonmelanoma skin cancer or cervical cancer in situ~* Contraindication for chemotherapy~* Malignant pleural or pericardial effusion.~* Women in pregnancy, lactation period, or no pregnancy test 14 days before the first dose~* Women who has the probability of pregnancy without contraception~* Tendency of hemorrhage~* In other clinical trials within 30 days~* Addicted in drugs or alcohol, AIDS patients~* Uncontrollable seizure or psychotic patients without self-control ability~* Severe allergy or idiosyncrasy~* Not suitable for this study judged by researchers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- split-course radiotherapy (Type: EXPERIMENTAL): The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to gross tumor. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is re-simulated. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).